Association of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status with total choline concentration and tumor volume in breast cancer patients: An MRI and in vivo proton MRS study

Magnetic Resonance in Medicine

Volumn 68, Issue 4, 2012, Pages 1039-1047

  Sah, Rani G ^a   Sharma, Uma ^a   Parshad, Rajinder ^a   Seenu, Vurthaluru ^a   Mathur, Sandeep R ^a   Jagannathan, Naranamangalam R ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

benign lesions; cutoff value; early breast cancer; estrogen receptor; human epidermal growth factor receptor 2; in vivo proton magnetic resonance spectroscopy; locally advanced breast cancer; malignant breast tissue; molecular biomarkers; progesterone receptor; total choline concentration; triple negative cancer; tumor volume

Indexed keywords

CELL PROLIFERATION; DISEASES; HISTOLOGY; MAGNETISM; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROTONS; TUMORS;

BENIGN LESION; BREAST TISSUES; CUT-OFF VALUE; EARLY BREAST CANCER; ESTROGEN RECEPTOR; HUMAN EPIDERMAL GROWTH FACTOR; IN-VIVO; LOCALLY ADVANCED BREAST CANCER; MOLECULAR BIOMARKER; PROGESTERONE RECEPTOR; TRIPLE NEGATIVE; TUMOR VOLUMES;

DIAGNOSIS;

CHOLINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; ADVANCED CANCER; ANGIOGENESIS; ARTICLE; BREAST CANCER; BREAST FIBROADENOMA; CANCER PATIENT; CANCER STAGING; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTOSARCOMA PHYLLOIDES; FEMALE; HUMAN; IN VIVO STUDY; MASTITIS; MENSTRUATION; MOLECULAR MECHANICS; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTON NUCLEAR MAGNETIC RESONANCE; TUMOR VOLUME;

EID: 84860494215     PISSN: 07403194     EISSN: 15222594     Source Type: Journal    
DOI: 10.1002/mrm.24117     Document Type: Article

References (41)

1. SÃrlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein LÃnning P, BÃrresen-Dale AL,. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci 2001; 98: 10869-10874.
2. Putti TC, El-Rehim DM, Rakha EA, Paish CE, Lee AH, Pinder SE, Ellis IO,. Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. Mod Pathol 2005; 18: 26-35.
3. De Giorgi U, Rosti G, Frassineti L, Kopf B, Giovannini N, Zumaglini F, Marangolo M,. High-dose chemotherapy for triple negative breast cancer. Ann Oncol 2007; 18: 202-203.
4. Kneeshaw PJ, Lowry M, Manton D, Hubbard A, Drew PJ, Turnbull LW,. Differentiation of benign from malignant breast disease associated with screening detected microcalcifications using dynamic contrast enhanced magnetic resonance imaging. Breast 2006; 15: 29-38.
5. Sharma U, Sharma R, Jagannathan NR,. Breast magnetic resonance imaging (breast MRI). In:, Harris RK, Wasylishen RE, editors. Encyclopedia of magnetic resonance. Chichester: Wiley; 2010.
6. Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, Morris E, Pisano E, Schnall M, Sener S, Smith RA, Warner E, Yaffe M, Andrews KS, Russell CA,; American Cancer Society Breast Cancer Advisory Group. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007; erratum in: CA Cancer J Clin 2007;57:185.
7. 1H NMR spectroscopic characterization of perchloric acid extracts from breast carcinomas and non-involved breast tissue. NMR Biomed 1994; 7: 181-194.
8. Roebuck JR, Cecil KM, Schnall MD, Lenkinski RE,. Human breast lesions: characterization with proton MR spectroscopy. Radiology 1998; 209: 269-275.
9. Jagannathan NR, Singh M, Govindaraju V, Raghunathan P, Coshic O, Julka PK, Rath GK,. Volume localized in vivo proton MR spectroscopy of breast carcinoma: Variation of W/F ratio in patients receiving chemotherapy. NMR Biomed 1998; 11: 414-422.
10. Jagannathan NR, Seenu V, Coshic O, Dwivedi SN, Julka PK, Srivastava A, Rath GK,. Evaluation of total choline from in vivo volume localized proton MR spectroscopy and its response to neoadjuvant chemotherapy in locally advanced breast cancer. Br J Cancer 2001; 84: 1016-1022.
11. Kartz-Brull R, Lavin PT, Lenkinsi RE,. Clinical utility of proton magnetic resonance spectroscopy in characterizing breast lesions. J Natl Cancer Inst 2002; 94: 1197-1202.
12. Sharma U, Jagannathan NR,. Breast magnetic resonance spectroscopy (MRS). In:, Harris RK, Wasylishen RE, editors. Encyclopedia of magnetic resonance. Chichester: Wiley; 2010.
13. Bartella L, Huang W,. Proton (1H) MR spectroscopy of the breast. Radiographics 2007; 27 (Suppl 1): S241-S252.
14. 1H MR spectroscopy to improve diagnostic accuracy of breast MR imaging: preliminary results of observer performance study at 4.0 T. Radiology 2005; 236: 465-475.
15. Jacobs MA, Barker PB, Bottomley PA, Bhujwalla Z, Bluemke DA,. Proton magnetic resonance spectroscopic imaging of human breast cancer: a preliminary study. J Magn Reson Imaging 2004; 19: 68-75.
16. 1H MRS at 1.5 T. Eur Radiol 2005; 15: 1037-1043.
17. Baek HM, Chen JH, Yu HJ, Mehta R, Nalcioglu O, Su MY,. Detection of choline signal in human breast lesions with chemical-shift imaging. J Magn Reson Imaging 2008; 27: 1114-1121.
18. Sah RG, Sharma U, Parshad R, Jagannathan NR,. Quantification of absolute concentration of choline for differentiation of malignant, benign and normal breast tissues by in vivo proton MR spectroscopy. In: Proceedings of the 17th Annual Meeting of ISMRM, Honolulu, Hawaii, USA, 2009. p 486.
19. Sah RG, Sharma U, Parshad R, Jagannathan NR,. Determination of cut-off value of total choline concentration (tCho) for the differentiation of malignant, benign and normal breast tissues by in vivo proton MR spectroscopy at 1.5 T in a large cohort of women. In: Proceedings of the 18th Annual Meeting of ISMRM, Stockholm, Sweden, Europe, 2010. p 3348.
20. 1H MR spectroscopy. Magn Reson Med 2003; 50: 1134-1143.
21. 1H MR spectroscopy using water as an internal reference at 1.5 T. MAGMA 2006; 19: 96-104.
22. Baek HM, Chen JH, Nalcioglu O, Su MY,. Choline as a biomarker for cell proliferation: do the results from proton MR spectroscopy show difference between HER2 positive and negative breast cancers? Int J Cancer 2008; 123: 1219-1221.
23. Haddadin IS, McIntosh A, Meisamy S, Corum C, Styczynski Snyder AL, Powell NJ, Nelson MT, Yee D, Garwood M, Bolan PJ,. Metabolite quantification and high-field MRS in breast cancer. NMR Biomed 2009; 22: 65-76.
24. Sardanelli F, Fausto A, Di Leo G, de Nijs R, Vorbuchner M, Podo F,. In vivo proton MR spectroscopy of the breast using the total choline peak integral as a marker of malignancy. Am J Roentgenol 2009: 192: 1608-1617.
25. Tse GM, Cheung HS, Pang LM, Chu WC, Law BK, Kung FY, Yeung DK,. Characterization of lesions of the breast with proton MR spectroscopy: comparison of carcinomas, benign lesions, and phyllodes tumors. Am J Roentgenol 2003; 181: 1267-1272.
26. Agrawal G, Chen JH, Baek HM, Hsiang D, Mehta RS, Nalcioglu O, Su MY,. MRI features of breast cancer: a correlation study with HER-2 receptor. Ann Oncol 2007; 18: 1903-1904.
27. Bakken IJ, Gribbestad IS, Singstad TE, Kvistad KA,. External standard method for the in vivo quantification of choline-containing compounds in breast tumors by proton MR spectroscopy at 1.5 tesla. Magn Reson Med 2001; 46: 189-192.
28. 31P NMR studies of cells and tumors. MAGMA 1998; 6: 44-52.
29. Glunde K, Jie C, Bhujwalla Z,. Molecular cause of aberrant choline phospholipid metabolism in breast cancer. Cancer Res 2004; 64: 4270-4276.
30. Danishad KA, Sharma U, Sah RG., Parshad R, Seenu V, Jagannathan NR,. Assessment of therapeutic response of locally advanced breast cancer (LABC) patients undergoing neoadjuvant chemotherapy (NACT) monitored using sequential magnetic resonance spectroscopic imaging (MRSI). NMR Biomed 2010; 23: 233-241.
31. 1H MR spectroscopy and dynamic contrast-enhanced MRI of human breast cancer. Magn Reson Imaging 2008; 26: 523-531.
32. McIntosh A, Bolan PJ, Meisamy S, Styczynski A, Everson LI, Nelson MT, Emory TH, Tuttle HM, Yee D, Garwood M,. Using quantitative choline measurements to predict axillary node status in human breast cancer, in vivo. In: Proceedings of the 13th Annual Meeting of ISMRM, Miami, Florida, USA, 2005. p 132.
33. Aboagye EO, Bhujwalla ZM,. Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res 1999; 59: 80-84.
34. Zheng L, Ren JQ, Chen Q, Zhang HP, Zhu HG,. The effect of HER2 over-expression on p53 gene expression, cell proliferation and sensitivity to gamma-irradiation via the PI3K/Akt pathway in breast cancer cell MCF7. Zhonghua Zhong Liu Za Zhi 2004; 26: 594-597.
35. Ménard S, Casalini P, Campiglio M, Pupa SM, Tagliabue E,. Role of HER2 in tumor progression and therapy. Cell Mol Life Sci 2004; 61: 2965-2978.
36. Holbro T, Civenni G, Hynes NE,. The ErbB receptors and their role in cancer progression. Exp Cell Res 2003; 284: 99-110.
37. Chen JH, Baek HM, Nalcioglu O, Su MY,. Estrogen receptor and breast MR imaging features: a correlation study. J Magn Reson Imaging 2008; 27: 825-833.
38. Koukourakis MI, Manolas C, Minopoulos G, Giatromanolaki A, Sivridis E,. Angiogenesis relates to estrogen receptor negativity, c-erbB-2 over-expression and early relapse in node-negative ductal carcinoma of the breast. Int J Surg Pathol 2003; 11: 29-34.
39. Fuckar D, Dekanic A, Stifter S, Mustac E, Krstulja M, Dobrila F, Jonjic N,. VEGF expression is associated with negative estrogen receptor status in patients with breast cancer. Int J Surg Pathol 2006; 14: 49-55.
40. 1H MR spectroscopy of invasive ductal carcinoma: correlations with FDG PET and histologic prognostic factors. Am J Roentgenol 2010; 194: 1384-1390.
41. Moestue SA, Borgan E, Huuse EM, Lindholm EM, Sitter B, BÃrresen-Dale AL, Engebraaten O, Maelandsmo GM, Gribbestad IS,. Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models. BMC Cancer 2010; 10: 433-444.